Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications,
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference
The presentation will be accessible via live webcast here. A webcast replay will be available for two weeks following the presentation in the Events section of NeuroPace’s Investor website at https://investors.neuropace.com.
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need.
Leerink analyst Faisal Khurshid downgraded Pliant Therapeutics (PLRX) to Market Perform from Outperform with a price target of $2, down from ...
Stock analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Schrödinger in a research report issued to clients and investors on Wednesday, February 26th. Leerink ...
Hosted on MSN13d
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform RecommendationFintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...
Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...
Equities research analysts at Leerink Partnrs issued their FY2026 EPS estimates for Kura Oncology in a note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst J. Chang ...
Leerink Partners analyst shifted the rating for Genmab A/S (NASDAQ:GMAB) stock from Market Perform to Outperform, maintaining a price target (PT) of $27.00. The upgrade reflects a positive long-term ...
Upstart investment bank SVB Leerink is no longer keeping mum on its ambitions to push into the red hot technology, media, and telecommunications market. The dealmaking unit of SVB Financial Group ...
Stock analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of DENTSPLY SIRONA in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback